Of H, Information P, Approval IUS, Drugs S, Disorder MD, Changes RM, et al
Monitoring your progress and making the right call The decision to continue, reduce, or stop GLP-1 therapy should be driven by data, not arbitrary timelines or gut feelings
Peptide medications, like most GLP-1 drugs, are especially challenging to deliver through the skins barrier because of their large molecular size
Regarding glucose-metabolism, two studies found that GLP-1(9-36), GLP-1 (7-36) and Liraglutide significantly inhibited insulin-stimulated glucose uptake [12, 13], with Liraglutide showing a dose dependent inhibition, with a maximum at a concentration of 1000 nM [12, 13]
Glucagon in diabetes Raskin and Unger reported hyperglucagonaemia in individuals with diabetes more than four decades ago [11] and this has been replicated in numerous studies [13, 20, 27]
2) Oral (Non-Liposomal) Standard oral capsules or drops are marketed for convenience, but peptides are prone to enzymatic breakdown in the GI tract